Cambridge Healthtech Institute’s 2nd Annual

Biomarkers for Immuno-Oncology

Predictive Biomarkers and Companion Diagnostics to Guide Cancer Immunotherapy
August 29-30, 2017 | Sheraton Boston | Boston, MA

As pharmaceutical and biotechnology companies increase their investment in immuno-oncology programs to facilitate rapid development of novel immunotherapies, there is increasing pressure to discover and validate relevant biomarkers. Cambridge Healthtech Institute’s Second Annual Biomarkers for Immuno-Oncology meeting will bring together biomarkers experts from industry and academia to address rapid development of predictive and prognostic IO biomarkers, utility of these biomarkers in clinical trials, and their potential as companion diagnostics.

Preliminary Agenda


PERSONALIZED CANCER IMMUNOTHERAPY: FROM PREDICTIVE BIOMARKERS TO COMPANION DIAGNOSTICS

Are Biomarkers Still Necessary for the Era of Immuno-Oncology?

Zhen Su, M.D., MBA, Senior Vice President, Global Head of Medical Affairs Oncology, EMD Serono

Biomarker Strategies for Precision Immune-Oncology

David Kaufman, M.D., Ph.D., Executive Director, Translational Immunology & Oncology, Merck Research Laboratories

Targeting Immune Responses in Multiple Myeloma

Raphael Clynes, M.D., Ph.D., Group Medical Director & Scientific Director, Human Immunology, Bristol-Myers Squibb

Discovery and Integration of Omic, Immune Profiling, and Imaging Biomarkers for Cancer Immunotherapy Development

Xingfeng Bao, Ph.D., Senior Principal Scientist & Head, Immuno-Oncology, Andover Innovative Medicine Institute, Eisai

Predictive Biomarkers in Immuno-Oncology

Jean-Marie Bruey, Ph.D., Companion Diagnostics Group Leader, Genentech

Building a Better Biomarker for Immune Therapy: Lessons Learned from Colon Cancer

Robert Anders, M.D., Ph.D., Associate Professor, Pathology, Johns Hopkins University

Evaluating the Clinical Utility of Circulating Tumor Cells to Predict Response to Checkpoint Immune Therapy

Terence Friedlander, M.D., Associate Clinical Professor, Hematology/Oncology, University of California, San Francisco


BIOMARKERS OF RESPONSE AND RESISTANCE TO IMMUNOTHERAPY

Molecular Biomarkers of Response to Keytruda

Andrey Loboda, Ph.D., Director, Genetics and Pharmacogenomics, Merck

Atezolizumab in Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Findings

Jakob Dupont, M.D., MA, Vice President, Global Head Breast & Gyn Cancer Development, Genentech, a Member of the Roche Group

Pathologic Response Patterns in Neoadjuvant Trials with Immunotherapy

Janis Taube, M.D., Associate Professor, Dermatology & Pathology, Johns Hopkins University

EMERGING INVESTIGATOR: Understanding the Heterogeneity and Dynamics of Responses to Checkpoint Blockade in Melanoma

Alexandre Reuben, Ph.D., Postdoctoral Fellow, Surgical Oncology, The University of Texas MD Anderson Cancer Center

EMERGING INVESTIGATOR: Biomarkers of Response/Progression in RCC Patients Receiving PD-1/PD-L1 Inhibitors

Aly-Khan Lalani, M.D., Genitourinary Oncology Fellow, Dana-Farber Cancer Center


GENOMIC BIOMARKERS FOR IMMUNOTHERAPY PATIENT SELECTION

Strategy for Development of Predictive Biomarkers for Immunotherapy

Ignacio I. Wistuba, M.D., Department Chair, Department of Translational Molecular Pathology, Division of Pathology & Lab Medicine, The University of Texas MD Anderson Cancer Center

Multi-Omics Artificial Intelligence-Based Approaches for Identifying Immunotherapy Responders

Olivier Elemento, Ph.D., Cancer Systems Biology and Precision Medicine, Weill Cornell Medicine




For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
juliab@healthtech.com

For exhibit & sponsorship opportunities, please contact: 
 
Rod Eymael
Manager, Business Development
781-247-6286
reymael@healthtech.com

YouTubeOutlookYouTubeLinkedInTwitter #IOSummit  

Japan-Flag   Korea-Flag   China-Simplified-Flag   China-Traditional-Flag

Register Today